Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma
Journal of Personalized Medicine · 23.01.2024 · 14 (2) · 128
DOI: 10.3390/jpm14020128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 23.01.2024. Verfasst von Eden C Andrew und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victorian Comprehensive Cancer Centre.
Abstract (Originalsprache)
Sarcomas are a heterogenous group of tumours that commonly carry poor prognosis with limited therapeutic options. Adolescents and young adults (AYAs) with sarcoma are a unique and understudied patient population that have only achieved modest survival gains compared to other groups. We present our institutional experience of AYAs with sarcoma who underwent comprehensive molecular profiling (CMP) via either large-panel targeted DNA sequencing or whole genome and transcriptome sequencing and evaluated the feasibility and clinical impact of this approach. Genomic variants detected were determined to be clinically relevant and actionable following evaluation by the Molecular Tumour Board. Clinicians provided feedback regarding the utility of testing three months after reporting. Twenty-five patients who were recruited for CMP are included in this analysis. The median time from consent to final molecular report was 45 days (interquartile range: 37–57). Potentially actionable variants were detected for 14 patients (56%), and new treatment recommendations were identified for 12 patients (48%). Pathogenic germline variants were identified in three patients (12%), and one patient had a change in diagnosis. The implementation of CMP for AYAs with sarcoma is clinically valuable, feasible, and should be increasingly integrated into routine clinical practice as technologies and turnaround times continue to improve.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, VIC 3000, Australia.
- Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC 3052, Australia.
- Victorian Adolescent and Young Adult Cancer Service, Parkville, VIC 3000, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.
- Department of Paediatrics, The University of Melbourne, Melbourne, VIC 3052, Australia.
- Centre for Cancer Research and Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC 3010, Australia.
ORCID-Profile: Eden C Andrew, Joseph H A Vissers, Stephen B Fox
Förderung
- Victorian Comprehensive Cancer Centre
Zitieren
APA
Andrew, E. C., Lewin, J., Desai, J., Orme, L., Hamilton, A., Bae, S., Zhu, W., Nicolson, S., Varghese, L. N., Mitchell, C. B., Vissers, J. H. A., Xu, H., Grimmond, S. M., Fox, S. B., & Luen, S. J. (2024). Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma. Journal of Personalized Medicine, 14(2), 128. https://doi.org/10.3390/jpm14020128
Vancouver
Andrew EC, Lewin J, Desai J, Orme L, Hamilton A, Bae S, et al. Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma. Journal of Personalized Medicine. 2024;14(2):128. doi:10.3390/jpm14020128
BibTeX
@article{Andrew2024,
author = {Andrew, Eden C and Lewin, Jeremy and Desai, Jayesh and Orme, Lisa and Hamilton, Anne and Bae, Susie and Zhu, Wenying and Nicolson, Shannon and Varghese, Leila N and Mitchell, Camilla B and Vissers, Joseph H A and Xu, Huiling and Grimmond, Sean M and Fox, Stephen B and Luen, Stephen J},
title = {Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {2},
pages = {128},
doi = {10.3390/jpm14020128}
}
EUVIMED